Amicus Therapeutics (NASDAQ:FOLD) Director Margaret G. Mcglynn sold 10,000 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $16.00, for a total value of $160,000.00. Following the completion of the sale, the director now directly owns 25,814 shares in the company, valued at approximately $413,024. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of FOLD stock traded up $0.18 during midday trading on Friday, reaching $16.74. 3,931,439 shares of the company traded hands, compared to its average volume of 2,565,064. Amicus Therapeutics has a 1-year low of $7.46 and a 1-year high of $17.40. The company has a current ratio of 4.21, a quick ratio of 4.15 and a debt-to-equity ratio of 0.32. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -5.73 and a beta of 1.48.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $16.78 million. sell-side analysts forecast that Amicus Therapeutics will post -1.26 earnings per share for the current fiscal year.
FOLD has been the topic of a number of analyst reports. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 10th. ValuEngine raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 7th. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. Finally, Leerink Swann lifted their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $19.06.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.